Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 161 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PSC Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

NCT05040659
View directory record Official record
Conditions
Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions
AROMHA Longitudinal Smell Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 6, 2026, 6:43 PM EDT
Withdrawn Not applicable Interventional

TDCS-potentiated Generalization of Cognitive Training in the Rehabilitation of Long COVID Symptoms

NCT05589272
View directory record Official record
Conditions
Post-acute Sequelae SARS-CoV-2 Infection (PASC)
Interventions
Active tDCS, Sham tDCS
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 6, 2026, 6:43 PM EDT
Recruiting No phase listed Observational

Immune-mediated Pathogenic Mechanisms of Neuro-PASC in Veterans

NCT06932237
View directory record Official record
Conditions
Neuro-PASC, Long COVID
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

RECOVER-SLEEP: Platform Protocol

NCT06404086
View directory record Official record
Conditions
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

NCT02464020
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions
Vancomycin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 6, 2026, 6:43 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LB-P8 low-dose, LB-P8 high-dose, Placebo
Drug
Lead sponsor
LISCure Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

NCT02061540
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LUM001
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

NCT02424175
View directory record Official record
Conditions
Sclerosing Cholangitis
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

NCT01456468
View directory record Official record
Conditions
Cholangitis, Sclerosing
Interventions
Oral all-trans retinoic acid (ATRA)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Not applicable Interventional

The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.

NCT01878838
View directory record Official record
Conditions
Nuclear Sclerosis of the Lens, Posterior Subcapsular Cataract, Cortical Cataract
Interventions
Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser, Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser
Procedure
Lead sponsor
Steven H. Linn, OD
Other
Eligibility
22 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
16
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Treatment of IgG4-Related Disease With Revlimid and Rituximab

NCT02705638
View directory record Official record
Conditions
Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis
Interventions
Rituximab, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

NCT02978339
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Curcumin
Drug
Lead sponsor
John E. Eaton
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

NCT06404060
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Education
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Results available

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

NCT03394781
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
DUR-928
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
San Francisco, California • Jacksonville, Florida • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 6, 2026, 6:43 PM EDT
Active, not recruiting Not applicable Interventional Results available

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT05092516
View directory record Official record
Conditions
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Completed No phase listed Observational

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

NCT03766035
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
SpyGlass DS I - II
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Davis, California • Sacramento, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)

NCT01220713
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post-Concussive Syndrome
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
19 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Portsmouth, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00002878
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, doxorubicin hydrochloride, valspodar, vincristine sulfate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
32
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 6, 2026, 6:43 PM EDT
Not yet recruiting No phase listed Observational

PET/MRI of Primary Sclerosing Cholangitis

NCT06252610
View directory record Official record
Conditions
PSC
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT04480840
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Pasadena, California • Redwood City, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 6, 2026, 6:43 PM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 6, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

NCT00001302
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasm, Lymphoma, Neoplasm Metastasis, Ovarian Cancer
Interventions
PSC 833
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 6:43 PM EDT